arrow
T

Tobias Neff

Merck & Co. Inc.
H指数:31
被引数:3,512

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma

随机、双盲、III期LEAP-003研究:比较一线仑伐替尼联合帕博利珠单抗与安慰剂联合帕博利珠单抗治疗不可切除或转移性黑色素瘤的疗效。

2025-08-280
PREAI
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
2021-01-203
OAAI
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Daratumumab单药治疗中危或高危阴燃性多发性骨髓瘤患者: 一项随机,开放标签,多中心,2期研究 (CENTAURUS)

LEUKEMIA
IF13.4
2020-02-0558
OAAI